Amneal Pharmaceuticals (NYSE:AMRX – Get Free Report) had its price objective boosted by analysts at Truist Financial from $4.00 to $6.00 in a research note issued to investors on Monday, Benzinga reports. The brokerage currently has a “buy” rating on the stock. Truist Financial’s price target points to a potential upside of 42.01% from the […]